New Legislation is Driving Diversity in Clinical Research
Industry leaders discuss how technology can help companies adapt to the regulatory changes and accomplish their DE&I goals.
A Need for Action
What are the necessary next steps—for all parties involved—in improving diversity in clinical trials?
Seeking Solutions for More Representative Populations
Exploring a human-centered, holistic approach for equitable trial outcomes.
The Missing Puzzle Pieces to Trial Representativeness
Truly moving the needle in clinical trial diversity comes down to embracing two fundamental pieces of the DE&I puzzle.
Q&A: Prioritizing Patient Diversity in Trial Design and Outreach
Tola Olorunnisola, senior vice president – general manager, clinical services and strategy, at Avantor, discusses the progress and challenges in incorporating more diversity-driven measures in drug development.
eCOA Libraries: An Untapped Opportunity?
Exploring ways to boost the adoption of eCOA provider-specific libraries—an often-frustrating migration process, but one with significant payoffs in simplified workflows and reduced timelines.
A Review of Critical Issues Detected Via Central Statistical Monitoring
Analysis assesses the relative percentage of quality issues detected via SDM that clinical study teams considered critical.
Calling Out ‘Check-the-Box’ Patient Engagement
Spotlight on poor compliance, access, and usefulness of trial results summaries.
Beyond the Iron Triangle: Behavioral Science Strategies
Leveraging an essential, new set of behaviorally informed best practices to break free from the constraints of the Iron Triangle of Clinical Trial Complexity.
Changing the Face—and Faces—of Clinical Research
The six steps to designing a successful diversity action plan for a clinical trial protocol.
Diversity in Clinical Trials: Strategies and Challenges
Why weighing all of the ‘DE&I’ components is critical at site and sponsor levels.
